Gallifen 200 mg/ml suspension for use in drinking water for chickens and pheasants

Authorised

- Fenbendazole

Product identification

Medicine name:
Gallifen 200 mg/ml suspension for use in drinking water for chickens and pheasants
Gallifen 200 mg/ml Zawiesina do podania w wodzie do picia

Active substance:
Fenbendazole

Target species:
Chicken
Pheasant

Route of administration:
In drinking water use

Product details

Active substance and strength:
Fenbendazole
200.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Suspension for use in drinking water

Withdrawal period by route of administration:

In drinking water use:

- **Chicken**

  - Eggs. 0 day

  - Meat and offal. 8 day * when used at 3 mg fenbendazole / kg bw / day

  - Meat and offal. 6 day

- **Pheasant**

  - Eggs. 0 day

  - Meat and offal. 6 day

Do not release pheasants for hunting for at least 6 days after the end of medication.

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP52AC13

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Poland

Package description:

White rectangular HDPE bottle of 1 litre with vertically see-through bar with an LDPE insert closed with white PP tamper- evident screw cap with a LDPE sealing disk.
White rectangular HDPE bottle of 1 litre with vertically see-through bar with an LDPE insert closed with white PP tamper- evident screw cap with a LDPE sealing disk.
White rectangular HDPE bottle of 1 litre with vertically see-through bar with an LDPE insert closed with white PP tamper- evident screw cap with a LDPE sealing disk.
White rectangular HDPE bottle of 1 litre with vertically see-through bar with an LDPE insert closed with white PP tamper- evident screw cap with a LDPE sealing disk.
White rectangular HDPE bottle of 1 litre with vertically see-through bar with an LDPE insert closed with white PP tamper- evident screw cap with a LDPE sealing disk.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
HuVepharma

Marketing authorisation date:
24/10/2018

Manufacturing sites for batch release:
Biovet J.S.C.

Responsible authority:
Office For Registration Of Medicinal Products Medical Devices And Biocidal Products

Authorisation number:
2822

Reference member state:
Ireland

Procedure number:
IE/V/0579/001

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia France Germany Greece Hungary Italy Latvia Lithuania Luxembourg Netherlands Poland Portugal Romania Slovakia Slovenia Spain

United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 11/02/2022
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
